COR: Ongoing Litigation Settlement And Buybacks Will Shape Healthcare Delivery Evolution

Key Takeaways

• Digital investments and capital allocation enhance efficiency, margin expansion, and strengthen Cencora's competitive edge amid regulatory and industry shifts.
  
• Specialty drug demand, aging populations, and targeted acquisitions support sustained revenue growth and long-term earnings resilience.
  
• Margin pressure, regulatory scrutiny, and intensifying competition threaten Cencora's revenue growth and profitability despite volume gains from newer and international product categories.

Catalysts

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.

• Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act, improving supply chain efficiency and transparency, which should drive higher net margins and operating income over time.
  
• The expanding demand for specialty drugs-driven by innovation in treatments for chronic diseases and new approvals in complex categories such as retina-supports robust volume growth in Cencora's high-margin specialty distribution and value-added services, directly benefiting future revenue and operating income.
  
• Cencora's global scale, local expertise, and strengthened specialty leadership (including recent acquisitions like Retina Consultants of America and investments like OneOncology) better position the company to capture growth opportunities from the aging population and rising chronic disease prevalence, supporting long-term sustained earnings growth.
  
• Strategic allocation of capital towards high-growth and highly aligned business units, while deemphasizing less strategic areas, allows for more disciplined investment, higher productivity, and an improved business mix, ultimately supporting margin expansion and resilient free cash flow.
  
• As industry and regulatory pressure for drug supply chain transparency increases, Cencora is well-positioned to benefit as a trusted and established partner, creating a potential competitive advantage over smaller or less compliant distributors, thereby supporting stable or growing market share and future revenue stability.

Cencora Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Cencora's revenue will grow by 7.3% annually over the next 3 years.
• Analysts assume that profit margins will increase from 0.5% today to 0.9% in 3 years time.
• Analysts expect earnings to reach $3.6 billion (and earnings per share of $19.74) by about March 2029, up from $1.6 billion today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 27.5x on those 2029 earnings, down from 39.2x today. This future PE is greater than the current PE for the US Healthcare industry at 21.4x.
• Analysts expect the number of shares outstanding to grow by 0.36% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

• The accelerated adoption of biosimilars and generics, while beneficial for healthcare affordability, is moderating top-line sales growth and compressing margins due to lower distribution fees on these products; this trend is likely to pressure Cencora's revenue growth and gross profit over time.
  
• Minimal profitability from high-volume products like GLP-1s means that even as these category sales increase, there is little positive impact on net earnings; if the growth in higher-margin specialty services slows, overall margin expansion could stall or reverse, impacting future earnings.
  
• International business faces ongoing headwinds, with operating income in the segment down due to persistent weakness in global specialty logistics and consulting services, and a slower-than-expected rebound in clinical trial activity; this softness can drag on consolidated margins and stifle overall earnings growth.
  
• Competitive pressures in specialty distribution, particularly as large customers expand their own specialty operations and as industry consolidation intensifies, risk eroding Cencora's negotiating leverage and market share, potentially reducing revenue and long-term profitability.
  
• Heightened policy and regulatory scrutiny-including government drug price negotiations (e.g., MFN, IRA implementation), shifts in drug reimbursement, and tariffs-pose structural headwinds that could compress both top-line revenue (through price pressure or loss of contracts) and increase compliance costs, impacting both revenue growth and net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $407.92 for Cencora based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $447.0, and the most bearish reporting a price target of just $340.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $402.7 billion, earnings will come to $3.6 billion, and it would be trading on a PE ratio of 27.5x, assuming you use a discount rate of 7.0%.
• Given the current share price of $327.27, the analyst price target of $407.92 is 19.8% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.